Objectives: To determine to what degree assessment of mobility based on comparison of videotape recordings before and after courses of physiotherapy in patients with chronic multiple sclerosis (MS) is reliable, correlates with ‘live’ assessments and indicates benefit.
Design: Prospective data collection within a randomized crossover controlled trial of physiotherapy at home, as an outpatient, or ‘no therapy’ in 40 patients.
Setting: Hospital outpatients: outpatient and home physiotherapy.
Outcomes: Mobility change based on a comparison of short video recordings before and after each treatment period was scored independently by two physiotherapists blinded to therapy type and other measures of outcome. Scores were compared with changes in the Rivermead Mobility Index (RMI) and other indices assessed by a physiotherapist in the patient's home.
Results: The two video observers agreed substantially on patient outcome. Changes in walking based on video correlated with RMI for home treatment (r = 0.41, p = 0.008) but not for hospital or no treatment periods (r = 0.14 and 0.15): video changes correlated with the ‘live’ assessor's global change score inconsistently (‘no therapy’r = 0.48, p = 0.002, hospital r = 0.30, p = 0.06 and home r = 0.17, p = 0.30 treatment periods). Based on video data alone, improved mobility was evident following home therapy for only one observer but not for the other or the averaged scores of both.
Conclusion: There was substantial agreement between two observers deciding on change in mobility based on independent blinded evaluation of short video sequences. However the correlations of these with ‘live’ assessments were variable. Physiotherapy had a less clear benefit on mobility based on video analysis alone compared with ‘live’ assessments. The study highlights the need for more objective measures of habitual mobility over longer periods.
Get full access to this article
View all access options for this article.
References
1.
Freeman J, Langdon D, Hobart J, Thompson AJ. The impact of rehabilitation on disability and handicap in progressive multiple sclerosis: a randomized controlled trial. Eur J Neurol1996; 3 (suppl 2): 15-15.
2.
Freeman JA, Langdon DW, Hobart JC, Thompson AJ. The impact of inpatient rehabilitation on progressive multiple sclerosis. Ann Neurol1997; 42: 236–244.
3.
Petajan JH, Gappmaier E, White AT, Spencer MK, Mino L, Hicks RW. Impact of aerobic training on fitness and quality of life in multiple sclerosis. Ann Neurol1996; 39: 432–441.
4.
Lord SE, Wade DT, Halligan PW. A comparison of two physiotherapy treatment approaches to improve walking in multiple sclerosis: a pilot randomized controlled study. Clin Rehabil1998; 12: 477–486.
5.
Solari A, Filippini G, Gasco P et al. Physical rehabilitation has a positive effect on disability in multiple sclerosis patients. Neurology1999; 52: 57–62.
6.
Wiles CM, Newcombe RG, Fuller KJ et al. Controlled randomised crossover trial of the effects of physiotherapy on mobility in chronic multiple sclerosis. J Neurol Neurosurg Psychiatry2001; 70: 174–179.
7.
Fuller KJ, Dawson K, Wiles CM. Physiotherapy in chronic MS: a controlled trial. Clin Rehabil1996; 10: 195–204.
8.
Collen FM, Wade DT, Robb GF, Bradshaw CM. The Rivermead Mobility Index: a further development of the Rivermead Motor Assessment. Int Disabil Stud1991; 13: 102–107.
9.
Poser CM, Paty DW, Scheinberg L et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol1983; 13: 227–231
10.
BohannonRW. Correlation of lower limb strengths and other variables with standing performance in stroke patients. Physiother Can1989; 41: 198–202.
11.
Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology1983; 33: 1444–1452.
12.
Lord SE, Halligan PW, Wade DT. Visual gait analysis: the development of a clinical assessment and scale. Clin Rehabil1998; 12: 107–119.
13.
Veltink PH, Bussmann HB, de Vries W, Martens WL, van Lummel RC. Detection of static and dynamic activities using uniaxial acclerometers. IEEE Trans Rehabil Eng1996; 4: 375–385
14.
Coleman KL, Smith DG, Boone DA, Joseph AW, del Aguila MA. Step activity monitor: long-term, continuous recording of ambulatory function. J Rehabil Res Dev1999; 36: 8–18.
15.
Swingler R, Compston DAS. The morbidity of multiple sclerosis. Q J Med1992; 83: 325–337.
16.
European Study Group. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet1998; 352: 1491–1497.
17.
Forbes RB, Lees A, Waugh N, Swingler RJ. Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis. BMJ1999; 319(7224): 1529–1533.
